Despite major advances, real-world data show diminishing survival outcomes and treatment-limiting toxicities in second line ...

Kalshi raises $185M at $2B valuation, signaling prediction market maturity and crypto sector growth amid regulatory challenges.

Osteoarthritis drug developer Paradigm says its purchase of an oral drug candidate won't distract it from its key phase III .

Harvard's pivot to privately funded research could reduce the burden on taxpayers and lead to more scientific breakthroughs.

For MBS investors, the ability to link data to specific loans and securities offers more precise analysis, alongside other advances in data and analytics ...

Kalshi founder Tarek Mansour announced on Wednesday that the online trading company that offers sports outcome contracts ...

Paradigm Biopharmaceuticals (ASX:PAR) has acquired the exclusive global rights to develop – and, of course, commercialise – a ...

U.S. companies are turning to Latin America (LatAm) to solve critical talent shortages and rising salary costs. With 75% of U ...

From ‘blitzscaling’ to leveraging network effects, China is using these same methods to dominate supply chain and disrupt ...

The market may be having a subdued start to the day but that hasn't stopped two ASX healthcare stocks from racing higher. Let ...

Popular prediction market Kalshi has raised $185 million at a $2  billion valuation after a "breakout year." The  prediction market said the Series C funding ...

The countdown has officially begun. ELCIA Tech Summit (ETS) 2025, the flagship gathering hosted by the Electronics City ...